These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 12972993)

  • 21. Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases?
    Kohlfuerst S; Igerc I; Gallowitsch HJ; Gomez I; Kresnik E; Matschnig S; Lind P
    Thyroid; 2006 Nov; 16(11):1113-9. PubMed ID: 17123338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Value of FDG PET imaging in the management of patients with thyroid, neuroendocrine, and neural crest tumors.
    Scanga DR; Martin WH; Delbeke D
    Clin Nucl Med; 2004 Feb; 29(2):86-90. PubMed ID: 14734903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine.
    Wang W; Larson SM; Tuttle RM; Kalaigian H; Kolbert K; Sonenberg M; Robbins RJ
    Thyroid; 2001 Dec; 11(12):1169-75. PubMed ID: 12186505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma.
    Moog F; Linke R; Manthey N; Tiling R; Knesewitsch P; Tatsch K; Hahn K
    J Nucl Med; 2000 Dec; 41(12):1989-95. PubMed ID: 11138683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of F-18-fluorodeoxyglucose positron emission tomography in the postoperative evaluation of differentiated thyroid cancer.
    Alzahrani AS; Abouzied ME; Salam SA; Mohamed G; Rifai A; Al Sugair A; Amin T
    Eur J Endocrinol; 2008 May; 158(5):683-9. PubMed ID: 18426827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 18F-FDG SPECT/CT in the diagnosis of differentiated thyroid carcinoma with elevated thyroglobulin and negative iodine-131 scans.
    Ma C; Wang X; Shao M; Zhao L; Jiawei X; Wu Z; Wang H
    Q J Nucl Med Mol Imaging; 2015 Jun; 59(2):220-7. PubMed ID: 24844253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complementary role of 18F-fluorodeoxyglucose positron emission tomography and 131I scan in the follow-up of post-therapy differentiated thyroid cancer.
    Hsu CH; Liu RS; Wu CH; Chen SM; Shih LS
    J Formos Med Assoc; 2002 Jul; 101(7):459-67. PubMed ID: 12353337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy.
    Helal BO; Merlet P; Toubert ME; Franc B; Schvartz C; Gauthier-Koelesnikov H; Prigent A; Syrota A
    J Nucl Med; 2001 Oct; 42(10):1464-9. PubMed ID: 11585858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
    Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
    J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic value and therapeutic impact of (18)F-FDG-PET/CT in differentiated thyroid cancer. Results of a German multicentre study.
    Riemann B; Uhrhan K; Dietlein M; Schmidt D; Kuwert T; Dorn R; Sciuk J; Kodalle T; Schober O
    Nuklearmedizin; 2013; 52(1):1-6. PubMed ID: 23192295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Positron emission tomography-computed tomography with (18)F-fluorodeoxyglucose in patients with recurrent differentiated thyroid carcinoma and negative radioiodine scan. Diagnostic performance and relation with tyroglobulin levels].
    Mariscal Labrador E; García Burillo A; Castell-Conesa J; Obiols Alfonso G; Kisiel González N; Barios Profitós M; Aguadé-Bruix S; Mesa Manteca J
    Rev Esp Med Nucl Imagen Mol; 2013; 32(3):146-51. PubMed ID: 22726673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma.
    Alnafisi NS; Driedger AA; Coates G; Moote DJ; Raphael SJ
    J Nucl Med; 2000 Jun; 41(6):1010-5. PubMed ID: 10855626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preoperative FDG-PET imaging to assess the malignant potential of follicular neoplasms of the thyroid.
    Smith RB; Robinson RA; Hoffman HT; Graham MM
    Otolaryngol Head Neck Surg; 2008 Jan; 138(1):101-6. PubMed ID: 18165002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm?
    Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
    Nuklearmedizin; 1998 Jan; 37(1):12-7. PubMed ID: 9467164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer.
    Grünwald F; Menzel C; Bender H; Palmedo H; Otte R; Fimmers R; Risse J; Biersack HJ
    J Nucl Med; 1998 Nov; 39(11):1903-6. PubMed ID: 9829580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Positron emission tomography for detecting iodine-131 nonvisualized metastasis of well-differentiated thyroid carcinoma: two case reports.
    Huang TS; Chieng PU; Chang CC; Yen RF
    J Endocrinol Invest; 1998 Jun; 21(6):392-8. PubMed ID: 9699132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Follicular thyroid carcinoma metastasis to the esophagus detected by 18FDG PET/CT.
    Lee B; Cook G; John L; Harrington K; Nutting C
    Thyroid; 2008 Feb; 18(2):267-71. PubMed ID: 18279026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study.
    Diehl M; Risse JH; Brandt-Mainz K; Dietlein M; Bohuslavizki KH; Matheja P; Lange H; Bredow J; Körber C; Grünwald F
    Eur J Nucl Med; 2001 Nov; 28(11):1671-6. PubMed ID: 11702109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical application of (18)F-FDG PET/CT to staging and treatment effectiveness monitoring of nasopharyngeal carcinoma].
    Wang GH; Lau EW; Shakher R; Binns DS; Hogg A; Drummond E; Hicks RJ
    Ai Zheng; 2007 Jun; 26(6):638-42. PubMed ID: 17562272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.